Clinical Associations of Bitter Taste Perception and Bitter Taste Receptor Variants and the Potential for Personalized Healthcare
DOI: https://doi.org/10.2147/PGPM.S390201
2023-02-12
Pharmacogenomics and Personalized Medicine
Abstract:Ziwen Mao, 1, 2 Weyland Cheng, 1, 2 Zhenwei Li, 2 Manye Yao, 2 Keming Sun 2 1 Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, Henan, People's Republic of China; 2 Department of Orthopaedic Surgery, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, Henan, People's Republic of China Correspondence: Weyland Cheng, Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, 33 Longhu Waihuan East Road, Zhengzhou, Henan, People's Republic of China, Tel +86 18502758200, Email Bitter taste receptors (T2Rs) consist of 25 functional receptors that can be found in various types of cells throughout the human body with responses ranging from detecting bitter taste to suppressing pathogen-induced inflammation upon activation. Numerous studies have observed clinical associations with genetic or phenotypic variants in bitter taste receptors, most notably that of the receptor isoform T2R38. With genetic variants playing a role in the response of the body to bacterial quorum-sensing molecules, bacterial metabolites, medicinal agonists and nutrients, we examine how T2R polymorphisms, expression levels and bitter taste perception can lead to varying clinical associations. From these genetic and phenotypic differences, healthcare management can potentially be individualized through appropriately administering drugs with bitter masking to increase compliance; optimizing nutritional strategies and diets; avoiding the use of T2R agonists if this pathway is already activated from bacterial infections; adjusting drug regimens based on differing prognoses; or adjusting drug regimens based on T2R expression levels in the target cell type and bodily region. Keywords: bitter taste receptors, TAS2R38, chronic rhinosinusitis, obesity, oral health, cancer Bitter taste receptors (T2Rs) are G-protein coupled receptors (GPCRs) that are classified as Frizzled/Taste2 family based on the GRAFS classification system. 1 The seven-transmembrane receptor is encoded by a gene family consisting of 25 functional genes, which leads to the expression of 25 functional receptor isoforms in the human body where they can be activated by various ligands. Activation of these receptors leads to the dissociation of the GPCR's heterotrimeric G-proteins. The Gα subunit upregulates phosphodiesterase, causing the hydrolyzation of cAMP, whereas the Gβγ subunit initiates the phospholipase Cβ2/inositol-1,4,5-triphosphate signaling pathway, releasing stored calcium from the endoplasmic reticulum into the cytoplasm. 2,3 In the gustatory system, bitter taste receptors are located in specialized epithelial taste receptor cells that reside in the taste bud. In the transduction pathway for bitter taste, the increase in intracellular calcium is followed by the release of ATP through the activation of calcium homeostasis modulator channels, thereby depolarizing the taste receptor cell. The released ATP subsequently activates ionotropic purinergic receptors on the sensory ganglion neurons that innervate the taste buds, thereby relaying bitter taste perception to the brain. 4 In recent years, there has been interest in the role of extraoral T2Rs in various diseases such as asthma, chronic rhinosinusitis, COVID-19, systemic inflammation, cancer, eczema and osteomyelitis. 5–10 Most studies have focused on extraoral T2Rs in the respiratory system where T2R activation can increase ciliary beat frequency, reduce inflammatory markers and emit anti-pathogenic substances, such as antimicrobial peptides and low levels of nitric oxide via endothelial nitric oxide synthase. 11,12 In immune cells such as lymphocytes, monocytes, granulocytes, leukocytes and mast cells, T2R activation can also decrease or inhibit pro-inflammatory cytokines such as TNF-alpha, IL-1β, IL-2, IL-4, IL-5, G-CSF, GM-CSF, MCP-1, histamine, PGD2, etc. 13,14 Other studies in literature have also found functional effects of T2Rs in the gastrointestinal, genitourinary, skin, cardiovascular and neurovascular system. 6,15–19 Here, we examine the phenotypic and genetic variations of bitter taste perception and T2Rs, mainly focusing on the more well-researched variation of T2R38. We discuss their clinical associations and significance and offer our perspectives on applying this knowledge in health management and towards future studies on personalizing medical treatments. T2R genes (TAS2R) have been no -Abstract Truncated-
pharmacology & pharmacy